<DOC>
	<DOCNO>NCT01506947</DOCNO>
	<brief_summary>This study prospective open label , non-randomised , single-arm , pilot clinical study evaluate Effect PTH Lowering erythropoietin consumption calcitriol resistant patient stage 5 chronic kidney disease .</brief_summary>
	<brief_title>A Prospective Open-Label , Non-randomised , Single-arm , Pilot Clinical Study Evaluating Effect PTH Lowering On Erythropoietin Consumption Calcitriol-Resistant Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>A subject include follow entry criterion meet : Patients &gt; =18 year age Stage 5 CKD patient receive hemodialysis moderate severe secondary hyperparathyroidism ( SHPT ) receive hemodialysis Patients anemia receive EPO therapy iron repletion ; Transferrin saturation ( TSAT ) &gt; 20 % Ferritin level &gt; 200 ng/mL require treatment erythropoietin ( EPO ) Patients Vitamin B level &gt; LLN Folic acid level &gt; LLN SATPatients Vitamin B level &gt; LLN Folic acid level &gt; LLN Patients treat intravenous calcitriol least 6 month Patients serum iPTH level &gt; 500 pg/mL Patients Ca . PO4 product &lt; 65 mg2/dL2 Patients willing sign `` write informed consent '' participate study related activity . Patients Ca level &lt; 6.5 mg/dL P level &lt; 11.2 mg/dL A subject exclude study he/she meet follow criterion : Patients know hypersensitivity and/or toxicity vitamin D metabolites and/or paricalcitol and/or product ingredient . Patients participate clinical study within last month . Patients whose previous concomitant medication laboratory data 6 month prior baseline visit available . Patients know contraindication selective Vitamin D receptor activator ( VDRAs ) accord SmPC . Pregnancy , Female patient pregnant , breastfeed planning pregnancy within next 6 month enrollment . Sexually active female patient accept appropriate contraceptive method course study also exclude . Hypertensive diabetic patient optimal steady medication regimen 30 day . Patients microcytic ( MCV &lt; 80 fL ) macrocytic ( MCV &gt; 100 fL ) anemia screen baseline may cause disease Micros Fe Deficiency , Thalassemias , Anemia Chronic Disease , Copper Deficiency , Zn poisoning , Sideroblastic Anemia , Macrosethanol abuse , myelodysplastic syndrome , acute myeloid leukemia , reticulocytosis , drug induce anemia , liver disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>Secondary hyperparathyroidism ,</keyword>
	<keyword>Chronic kidney disease</keyword>
</DOC>